Combination chemotherapy comprising a liposomal prodrug of mitomycin C
US10080807B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 9, 2015 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Jun 15, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is based on a finding of an unexpected synergistic and safe combination of antineoplastic agents which when administered in combination provides greater efficacy than the single agents alone. Accordingly, a method of treating neoplasia in a subject in need of treatment is provided, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C, in combination with an amount of a chemotherapeutic agent. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin C. Together, the prodrug of mitomycin C and chemotherapeutic agent provide a synergistic antineoplastic effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.